Mathur Pankaj, Ostadal Bohuslav, Romeo Francesco, Mehta Jawahar L
Cardiovascular Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, 4301 West Markham St., Little Rock, AR, 72205, USA,
Cardiovasc Drugs Ther. 2015 Aug;29(4):319-27. doi: 10.1007/s10557-015-6596-3.
Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Considerable research has been done over the last several decades to understand the pathophysiology of atherosclerosis. It is widely believed that estrogen is responsible for the protection of women from CVD in the premenopausal age group. However, hormone replacement therapy has failed to decrease CVD events in clinical studies which points to the complexity of the relationship between vascular biology and estrogen hormones. Interestingly, preponderance of vascular and connective tissue disorders in women also points to an inherent role of hormones and tissue factors in maintenance of vascular endothelial function. The differential effect of GPER, lipoprotein A, TLRs, leucocyte-platelet aggregate markers in men and women also suggests inherent gender-related differences in the pathophysiology of atherosclerosis. A better understanding of the pathophysiology is likely to open ways to improve evidence-based treatment of CVD in women.
动脉粥样硬化性心血管疾病(CVD)是全球发病和死亡的主要原因。在过去几十年里,人们进行了大量研究以了解动脉粥样硬化的病理生理学。人们普遍认为,雌激素可保护绝经前年龄组的女性免受CVD影响。然而,激素替代疗法在临床研究中未能减少CVD事件,这表明血管生物学与雌激素之间关系复杂。有趣的是,女性血管和结缔组织疾病的高发也表明激素和组织因子在维持血管内皮功能方面具有内在作用。男性和女性中G蛋白偶联雌激素受体(GPER)、脂蛋白A、Toll样受体(TLRs)、白细胞 - 血小板聚集标志物的差异效应也表明动脉粥样硬化病理生理学中存在固有的性别差异。更好地理解病理生理学可能会为改善女性CVD的循证治疗开辟道路。